Trade Johnson & Johnson - JNJ CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.26 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Johnson & Johnson ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 158.11 |
Open* | 158.08 |
1-Year Change* | 3.71% |
Day's Range* | 156.51 - 158.13 |
52 wk Range | 144.95-175.97 |
Average Volume (10 days) | 5.70M |
Average Volume (3 months) | 137.48M |
Market Cap | 388.08B |
P/E Ratio | 32.81 |
Shares Outstanding | 2.41B |
Revenue | 87.47B |
EPS | 4.91 |
Dividend (Yield %) | 2.95267 |
Beta | 0.53 |
Next Earnings Date | Jan 23, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 18, 2024 | 156.65 | -1.43 | -0.90% | 158.08 | 158.49 | 156.45 |
Mar 15, 2024 | 158.11 | -0.96 | -0.60% | 159.07 | 159.35 | 157.03 |
Mar 14, 2024 | 159.01 | -1.96 | -1.22% | 160.97 | 161.54 | 158.50 |
Mar 13, 2024 | 160.73 | -1.69 | -1.04% | 162.42 | 162.83 | 159.71 |
Mar 12, 2024 | 162.76 | 2.01 | 1.25% | 160.75 | 163.05 | 160.25 |
Mar 11, 2024 | 161.19 | 2.23 | 1.40% | 158.96 | 161.35 | 158.55 |
Mar 8, 2024 | 159.49 | 0.93 | 0.59% | 158.56 | 160.33 | 158.08 |
Mar 7, 2024 | 158.71 | -0.48 | -0.30% | 159.19 | 160.29 | 157.95 |
Mar 6, 2024 | 159.31 | -0.59 | -0.37% | 159.90 | 160.86 | 158.66 |
Mar 5, 2024 | 160.02 | 0.39 | 0.24% | 159.63 | 161.18 | 159.14 |
Mar 4, 2024 | 159.76 | -2.34 | -1.44% | 162.10 | 162.45 | 158.21 |
Mar 1, 2024 | 161.96 | 0.56 | 0.35% | 161.40 | 162.49 | 160.74 |
Feb 29, 2024 | 161.35 | -0.05 | -0.03% | 161.40 | 162.12 | 160.59 |
Feb 28, 2024 | 161.26 | 0.41 | 0.25% | 160.85 | 161.55 | 159.95 |
Feb 27, 2024 | 160.96 | 0.96 | 0.60% | 160.00 | 160.99 | 159.60 |
Feb 26, 2024 | 160.50 | -0.81 | -0.50% | 161.31 | 161.92 | 160.50 |
Feb 23, 2024 | 161.60 | 1.20 | 0.75% | 160.40 | 162.19 | 160.11 |
Feb 22, 2024 | 160.99 | 2.67 | 1.69% | 158.32 | 160.99 | 157.69 |
Feb 21, 2024 | 157.51 | 0.20 | 0.13% | 157.31 | 158.64 | 156.83 |
Feb 20, 2024 | 157.55 | 1.05 | 0.67% | 156.50 | 158.55 | 155.95 |
Johnson & Johnson Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, April 16, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 Johnson & Johnson Earnings Release Q1 2024 Johnson & Johnson Earnings ReleaseForecast -Previous - |
Friday, April 26, 2024 | ||
Time (UTC) 14:00 | Country US
| Event Johnson & Johnson Annual Shareholders Meeting Johnson & Johnson Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 94943 | 93775 | 82584 | 82059 | 81581 |
Revenue | 94943 | 93775 | 82584 | 82059 | 81581 |
Cost of Revenue, Total | 30989 | 29855 | 28327 | 27456 | 26986 |
Gross Profit | 63954 | 63920 | 54257 | 54603 | 54595 |
Total Operating Expense | 73218 | 70999 | 66087 | 64731 | 63582 |
Selling/General/Admin. Expenses, Total | 24765 | 24659 | 22084 | 22178 | 22540 |
Research & Development | 14603 | 14714 | 12159 | 11355 | 10775 |
Interest Expense (Income) - Net Operating | 814 | -370 | -410 | -183 | 394 |
Unusual Expense (Income) | 5004 | 4041 | 4428 | 1456 | 1826 |
Other Operating Expenses, Total | -2957 | -1900 | -501 | 2469 | 1061 |
Operating Income | 21725 | 22776 | 16497 | 17328 | 17999 |
Net Income Before Taxes | 21725 | 22776 | 16497 | 17328 | 17999 |
Net Income After Taxes | 17941 | 20878 | 14414 | 15119 | 15297 |
Net Income Before Extra. Items | 17941 | 20878 | 14414 | 15119 | 15297 |
Net Income | 17941 | 20878 | 14714 | 15119 | 15297 |
Income Available to Common Excl. Extra. Items | 17941 | 20878 | 14414 | 15119 | 15297 |
Income Available to Common Incl. Extra. Items | 17941 | 20878 | 14714 | 15119 | 15297 |
Diluted Net Income | 17941 | 20878 | 14714 | 15119 | 15297 |
Diluted Weighted Average Shares | 2663.9 | 2674 | 2670.7 | 2684.3 | 2728.7 |
Diluted EPS Excluding Extraordinary Items | 6.73486 | 7.80778 | 5.39709 | 5.63238 | 5.60597 |
Dividends per Share - Common Stock Primary Issue | 4.45 | 4.19 | 3.98 | 3.75 | 3.54 |
Diluted Normalized EPS | 8.67833 | 9.22111 | 6.98515 | 7.87 | 6.92185 |
Total Extraordinary Items | 300 |
Oct 2023 | Jul 2023 | Apr 2023 | Apr 2023 | Jan 2023 | |
---|---|---|---|---|---|
Total revenue | 21351 | 42413 | 24746 | 24746 | 23706 |
Revenue | 21351 | 42413 | 24746 | 24746 | 23706 |
Cost of Revenue, Total | 6606 | 13149 | 8395 | 8395 | 7711 |
Gross Profit | 14745 | 29264 | 16351 | 16351 | 15995 |
Total Operating Expense | 16134 | 37394 | 25483 | 25483 | 19505 |
Selling/General/Admin. Expenses, Total | 5400 | 10302 | 6138 | 6138 | 6512 |
Research & Development | 3447 | 7158 | 3563 | 3563 | 3841 |
Interest Expense (Income) - Net Operating | -182 | -95 | -20 | 80 | -77 |
Unusual Expense (Income) | 364 | 324 | 179 | 7579 | 1871.2 |
Other Operating Expenses, Total | 499 | 6556 | 7228 | -272 | -353.2 |
Operating Income | 5217 | 5019 | -737 | -737 | 4201 |
Net Income Before Taxes | 5217 | 5019 | -737 | -737 | 4201 |
Net Income After Taxes | 4309 | 4885 | -68 | -68 | 3520 |
Net Income Before Extra. Items | 4309 | 4885 | -68 | -68 | 3520 |
Net Income | 26028 | 5076 | -68 | -68 | 3520 |
Income Available to Common Excl. Extra. Items | 4309 | 4885 | -68 | -68 | 3520 |
Income Available to Common Incl. Extra. Items | 26028 | 5076 | -68 | -68 | 3520 |
Diluted Net Income | 26028 | 5076 | -68 | -68 | 3520 |
Diluted Weighted Average Shares | 2549.7 | 2576.55 | 2605.5 | 2605.5 | 2653.1 |
Diluted EPS Excluding Extraordinary Items | 1.69 | 1.89595 | -0.0261 | -0.0261 | 1.32675 |
Dividends per Share - Common Stock Primary Issue | 1.19 | 2.32 | 1.13 | 1.13 | 1.13 |
Diluted Normalized EPS | 2.0928 | 5.98514 | 3.81117 | 1.87123 | 2.02302 |
Total Extraordinary Items | 21719 | 191 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 55294 | 60979 | 51237 | 45274 | 46033 |
Cash and Short Term Investments | 23519 | 31608 | 25185 | 19287 | 19687 |
Cash | 4926 | 2936 | 2863 | 2637 | 2619 |
Cash & Equivalents | 5368 | 1901 | 2102 | 2864 | 3397 |
Short Term Investments | 13225 | 26771 | 20220 | 13786 | 13671 |
Total Receivables, Net | 16160 | 15283 | 13576 | 14481 | 14098 |
Accounts Receivable - Trade, Net | 16160 | 15283 | 13576 | 14481 | 14098 |
Total Inventory | 12483 | 10387 | 9344 | 9020 | 8599 |
Prepaid Expenses | 3132 | 3701 | 3132 | 2392 | 2699 |
Total Assets | 187378 | 182018 | 174894 | 157728 | 152954 |
Property/Plant/Equipment, Total - Net | 20903 | 19862 | 19766 | 18615 | 17035 |
Property/Plant/Equipment, Total - Gross | 50353 | 48579 | 47804 | 44289 | 41851 |
Accumulated Depreciation, Total | -29450 | -28717 | -28038 | -25674 | -24816 |
Goodwill, Net | 45231 | 35246 | 36393 | 33639 | 30453 |
Intangibles, Net | 48325 | 46392 | 53402 | 47643 | 47611 |
Other Long Term Assets, Total | 17049 | 17655 | 12615 | 11409 | 11311 |
Total Current Liabilities | 55802 | 45226 | 42493 | 35964 | 31230 |
Accounts Payable | 11703 | 11055 | 9505 | 8544 | 7537 |
Accrued Expenses | 29201 | 29293 | 28965 | 23952 | 20079 |
Notes Payable/Short Term Debt | 11220 | 1635 | 832 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1551 | 2131 | 1799 | 1202 | 2297 |
Other Current Liabilities, Total | 2127 | 1112 | 1392 | 2266 | 1317 |
Total Liabilities | 110574 | 107995 | 111616 | 98257 | 93202 |
Total Long Term Debt | 26888 | 29985 | 32635 | 26494 | 27684 |
Long Term Debt | 26888 | 29985 | 32635 | 26494 | 27684 |
Deferred Income Tax | 6374 | 7487 | 7214 | 5958 | 7506 |
Other Liabilities, Total | 21510 | 25297 | 29274 | 29841 | 26782 |
Total Equity | 76804 | 74023 | 63278 | 59471 | 59752 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 3120 | 3120 | 3120 | 3120 | 3120 |
Retained Earnings (Accumulated Deficit) | 128345 | 123060 | 113890 | 110659 | 106216 |
Treasury Stock - Common | -41694 | -39099 | -38490 | -38417 | -34362 |
Unrealized Gain (Loss) | -27 | -3 | 1 | 0 | 0 |
Other Equity, Total | -12940 | -13055 | -15243 | -15891 | -15222 |
Total Liabilities & Shareholders’ Equity | 187378 | 182018 | 174894 | 157728 | 152954 |
Total Common Shares Outstanding | 2613.6 | 2628.97 | 2632.51 | 2632.51 | 2662.32 |
Other Current Assets, Total | 0 | 94 | 950 | ||
Long Term Investments | 576 | 1884 | 1481 | 1148 | 511 |
Oct 2023 | Jul 2023 | Apr 2023 | Apr 2023 | Jan 2023 | |
---|---|---|---|---|---|
Total Current Assets | 53703 | 60567 | 64388 | 55294 | |
Cash and Short Term Investments | 23511 | 28505 | 24613 | 23519 | |
Cash | 3214 | 4430 | 4674 | 4926 | |
Cash & Equivalents | 3503 | 3570 | 3364 | 5368 | |
Short Term Investments | 16794 | 20505 | 16575 | 13225 | |
Total Receivables, Net | 14798 | 16777 | 16350 | 16160 | |
Accounts Receivable - Trade, Net | 14798 | 16777 | 16350 | 16160 | |
Total Inventory | 11198 | 12888 | 12809 | 12483 | |
Prepaid Expenses | 4196 | 2397 | 2921 | 3132 | |
Total Assets | 166061 | 191686 | 195969 | 187378 | |
Property/Plant/Equipment, Total - Net | 18821 | 20576 | 20174 | 20903 | |
Property/Plant/Equipment, Total - Gross | 45626 | 51218 | 50367 | 49253 | |
Accumulated Depreciation, Total | -26805 | -30642 | -30193 | -29450 | |
Goodwill, Net | 36124 | 45440 | 45575 | 45231 | |
Intangibles, Net | 35021 | 46246 | 47448 | 48325 | |
Long Term Investments | 4023 | 493 | 505 | 576 | |
Other Long Term Assets, Total | 18369 | 18364 | 17879 | 17049 | |
Total Current Liabilities | 44370 | 54170 | 60373 | 55802 | |
Accounts Payable | 8355 | 10443 | 9909 | 11703 | |
Accrued Expenses | 29246 | 29339 | 28219 | 29201 | |
Notes Payable/Short Term Debt | 2000 | 9800 | 16900 | 11220 | |
Current Port. of LT Debt/Capital Leases | 1870 | 1901 | 1079 | 1551 | |
Other Current Liabilities, Total | 2899 | 2687 | 4266 | 2127 | |
Total Liabilities | 94833 | 116537 | 125100 | 110574 | |
Total Long Term Debt | 26051 | 33901 | 34928 | 26888 | |
Long Term Debt | 26051 | 33901 | 34928 | 26888 | |
Deferred Income Tax | 2623 | 3627 | 4417 | 6374 | |
Other Liabilities, Total | 21789 | 23579 | 25382 | 21510 | |
Total Equity | 71228 | 75149 | 70869 | 76804 | |
Common Stock | 3120 | 3120 | 3120 | 3120 | |
Retained Earnings (Accumulated Deficit) | 152536 | 129381 | 124558 | 128345 | |
Treasury Stock - Common | -75648 | -44217 | -44183 | -41694 | |
Unrealized Gain (Loss) | -2 | -6 | -10 | -27 | |
Other Equity, Total | -8778 | -13129 | -12616 | -12940 | |
Total Liabilities & Shareholders’ Equity | 166061 | 191686 | 195969 | 187378 | |
Total Common Shares Outstanding | 2407.18 | 2598.14 | 2598.32 | 2613.6 | |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Other Current Assets, Total | 0 | 7695 | |||
Minority Interest | 1260 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 17941 | 20878 | 14714 | 15119 | 15297 |
Cash From Operating Activities | 21194 | 23410 | 23536 | 23416 | 22201 |
Cash From Operating Activities | 6970 | 7390 | 7231 | 7009 | 6929 |
Deferred Taxes | -1663 | -2079 | -1141 | -2476 | -1016 |
Non-Cash Items | 1957 | 1459 | 42 | -101 | 988 |
Cash Taxes Paid | 5223 | 4768 | 4619 | 4191 | 4570 |
Cash Interest Paid | 1915 | 990 | 904 | 995 | 1049 |
Changes in Working Capital | -4011 | -4238 | 2690 | 3865 | 3 |
Cash From Investing Activities | -12371 | -8683 | -20825 | -6194 | -3167 |
Capital Expenditures | -4009 | -3652 | -3347 | -3498 | -3670 |
Other Investing Cash Flow Items, Total | -8362 | -5031 | -17478 | -2696 | 503 |
Cash From Financing Activities | -8871 | -14047 | -6120 | -18015 | -18510 |
Financing Cash Flow Items | 65 | 395 | -627 | 575 | -148 |
Total Cash Dividends Paid | -11682 | -11032 | -10481 | -9917 | -9494 |
Issuance (Retirement) of Stock, Net | -4706 | -2420 | -2107 | -5792 | -4919 |
Issuance (Retirement) of Debt, Net | 7452 | -990 | 7095 | -2881 | -3949 |
Foreign Exchange Effects | -312 | -178 | 89 | -9 | -241 |
Net Change in Cash | -360 | 502 | -3320 | -802 | 283 |
Apr 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -68 | 17941 | 14421 | 9963 | |
Cash From Operating Activities | 3257 | 21194 | 15844 | 9560 | |
Cash From Operating Activities | 1880 | 6970 | 5198 | 3513 | |
Deferred Taxes | -1543 | -1663 | -2488 | -2349 | |
Non-Cash Items | 725 | 1957 | 1485 | 1175 | |
Changes in Working Capital | 2263 | -4011 | -2772 | -2742 | |
Cash From Investing Activities | 3315 | -12371 | -7974 | -6273 | |
Capital Expenditures | -863 | -4009 | -2422 | -1470 | |
Other Investing Cash Flow Items, Total | 4178 | -8362 | -5552 | -4803 | |
Cash From Financing Activities | 6138 | -8871 | -10571 | -6646 | |
Financing Cash Flow Items | -252 | 65 | 1806 | 802 | |
Total Cash Dividends Paid | -2942 | -11682 | -8728 | -5758 | |
Issuance (Retirement) of Stock, Net | -3548 | -4706 | -3808 | -1730 | |
Issuance (Retirement) of Debt, Net | 12880 | 7452 | 159 | 40 | |
Foreign Exchange Effects | 28 | -312 | -431 | -145 | |
Net Change in Cash | 12738 | -360 | -3132 | -3504 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 10.2364 | 246418524 | 569768 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.8919 | 141833756 | 1568633 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.3464 | 128702928 | -1152148 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0645 | 49697798 | 990298 | 2023-06-30 | LOW |
State Farm Insurance Companies | Insurance Company | 1.3158 | 31675492 | 0 | 2023-06-30 | LOW |
Capital International Investors | Investment Advisor | 1.1559 | 27825795 | 10724110 | 2023-06-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0839 | 26093398 | 2295051 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.0094 | 24299765 | 1144263 | 2023-06-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 0.9536 | 22955840 | -2430935 | 2023-06-30 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.9286 | 22355142 | 92730 | 2023-06-30 | LOW |
MFS Investment Management | Investment Advisor/Hedge Fund | 0.8351 | 20102965 | -288668 | 2023-06-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.8273 | 19914659 | -1746201 | 2023-06-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.8218 | 19782007 | 1046097 | 2023-06-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 0.7857 | 18913505 | 2153767 | 2023-06-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.7352 | 17697419 | 2080595 | 2023-06-30 | LOW |
Wells Fargo Advisors | Research Firm | 0.7142 | 17193465 | 15312 | 2023-06-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.7113 | 17123285 | -23034 | 2023-06-30 | LOW |
BofA Global Research (US) | Research Firm | 0.7069 | 17017658 | -3806531 | 2023-06-30 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.6824 | 16427920 | 117449 | 2023-06-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.6704 | 16139108 | -242372 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Johnson & Johnson Company profile
What is Johnson & Johnson?
Johnson & Johnson is a holding company with its subsidiaries involved in the production and distribution of consumer healthcare products, medical devices and pharmaceutical products. Its consumer segment is represented by the brands Johnson's, Clean & Clear, Le Petite Marseillais and others. The pharmaceutical division ships products for almost all therapeutic fields and treatments for autoimmune disorders. The medical division manufactures devices for orthopaedic, diabetes care and other fields.
Financial stability has been one of Johnson & Johnson’s hallmarks for decades. The company has raised its dividend for 55 successive years, and remains one of just two U.S. companies to have a triple-A credit rating.Fortune included Johnson & Johnson in its list of the largest American corporations.
Johnson & Johnson also prides itself on its corporate social responsibility, and sets out its values in a Credo. In it, the company declares: “We believe our first responsibility is to the doctors, nurses and patients, to mothers and fathers and all others who use our products and services […] We must constantly strive to reduce our costs in order to maintain reasonable prices […] Our suppliers and distributors must have an opportunity to make a fair profit.”
Who are the key people at Johnson & Johnson?
Alex Gorsky is Chairman of the Board of Directors and Chief Executive Officer. Other key figures include Chief Financial Officer Dominic Caruso; Joaquin Duato, Worldwide Chairman, Pharmaceuticals; Jorge Mesquita, Worldwide Chairman, Consumer; and Ashley McEvoy, Company Group Chairman, Consumer Medical Devices.
What is the modern history of Johnson & Johnson?
Johnson & Johnson was founded by three brothers in 1885, incorporated in 1887, and chaired by successive members of the Johnson family until 1963. The company was listed in 1944 and steadily expanded from its home market to Latin America, Europe, Africa and Asia. In 1959, Johnson & Johnson acquired pharmaceutical manufacturer Cilag AG – a big landmark for its pharmaceutical division. The medical and consumer health divisions saw major growth in the latter decades of the 20thcentury.
What are the latest developments at Johnson & Johnson?
In its full year 2017 results, Johnson & Johnson reported worldwide sales of $76.5 billion, an increase of 6.3% on the previous year.Excluding the impact of acquisitions and divestitures, worldwide sales for 2017 were 2.4% higher than in 2016.Net earnings for the full year 2017 were $1.3 billion, and adjusted full year earnings per share were $7.30, an increase of 8.5% on 2016.
The Johnson & Johnson share price, which hovered between $50 and $60 for most of the first decade of this century, started taking off in 2012. By May 2014 the shares were trading at over $100, and in January 2018 they went as high as $147. As of 3 April 2018, they stood at just over $127. To find out how the shares are doing right now, follow Capital.com. Our JNJ chart puts all the information at your fingertips.
Where does Johnson & Johnson operate?
Johnson & Johnson is headquartered in New Brunswick in the U.S. state of New Jersey. The company’s 250 or so subsidiaries operate in 60 countries around the world, and its products are sold in more than 175 countries. So it’s a truly global company, with high levels of brand recognition.
Where is Johnson & Johnson traded?
Johnson & Johnson is listed on the New York Stock Exchange (NYSE), and the shares are a component of the Dow Jones Industrial Average. Check out Capital.com for the latest JNJ chart. We’ll keep you up to date and in the picture.
Industry: | Pharmaceuticals (NEC) |
One Johnson & Johnson Plaza
NEW BRUNSWICK
NEW JERSEY 08933
US
Income Statement
- Annual
- Quarterly
News
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?
UK banks will be in the spotlight in the week ahead as the European earnings season continues
16:38, 16 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com